NLRP11

Summary

NLRP11 (NLR family pyrin domain containing 11, HGNC:22945) is a protein-coding gene on chromosome 19q13.43, encoding NACHT, LRR and PYD domains-containing protein 11 (P59045). Involved in inflammation.

This gene is a member of the the NOD-like receptor protein (NLRP) gene family and encodes a protein with an N-terminal pyrin death (PYD) domain and nucleoside triphosphate hydrolase (NACHT) domain and a C-terminal leucine-rich repeats (LRR) region. This gene has been shown to regulate caspases in the proinflammatory signal transduction pathway and, based on studies of other members of the NLRP gene family with similar domain structure, is predicted to form part of the multiprotein inflammasome complex. Alternative splicing produces multiple transcript variants encoding distince isoforms.

Source: NCBI Gene 204801 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 7
• Clinical variants (ClinVar): 185 total
• MANE Select transcript: NM_001394894

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22945
Approved symbol	NLRP11
Name	NLR family pyrin domain containing 11
Location	19q13.43
Locus type	gene with protein product
Status	Approved
Aliases	PYPAF6, NOD17, PAN10, CLR19.6
Ensembl gene	ENSG00000179873
Ensembl biotype	protein_coding
OMIM	609664
Entrez	204801

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 nonsense_mediated_decay

ENST00000589093, ENST00000589824, ENST00000590409, ENST00000592953, ENST00000593208, ENST00000593244

RefSeq mRNA: 5 — MANE Select: NM_001394894 NM_001297743, NM_001385451, NM_001385453, NM_001394894, NM_145007

CCDS: CCDS12935, CCDS74458, CCDS92693

Canonical transcript exons

ENST00000589093 — 10 exons

Exon	Start	End
ENSE00001246574	55801572	55801739
ENSE00001246582	55807853	55808014
ENSE00001400385	55817904	55818236
ENSE00003458648	55788807	55788977
ENSE00003468634	55796080	55796250
ENSE00003523569	55792301	55792471
ENSE00003526792	55808769	55810338
ENSE00003599188	55789229	55789399
ENSE00003978271	55785399	55785871
ENSE00003978272	55831963	55831999

Expression profiles

Bgee: expression breadth broad, 36 present calls, max score 99.87.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1105 / max 51.3215, expressed in 17 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
182861	0.0565	9
182862	0.0190	4
182859	0.0178	5
182860	0.0172	4

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.87	gold quality
oocyte	CL:0000023	99.81	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.89	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	64.81	gold quality
bone marrow cell	CL:0002092	53.90	silver quality
right lobe of liver	UBERON:0001114	53.87	gold quality
testis	UBERON:0000473	52.57	gold quality
sperm	CL:0000019	52.32	gold quality
right testis	UBERON:0004534	52.17	gold quality
islet of Langerhans	UBERON:0000006	51.92	gold quality
skin of hip	UBERON:0001554	51.90	silver quality
left testis	UBERON:0004533	50.93	gold quality
liver	UBERON:0002107	49.94	gold quality
corpus epididymis	UBERON:0004359	47.87	gold quality
lymph node	UBERON:0000029	46.00	gold quality
gall bladder	UBERON:0002110	45.93	gold quality
cortex of kidney	UBERON:0001225	45.46	gold quality
tonsil	UBERON:0002372	45.13	gold quality
rectum	UBERON:0001052	44.98	gold quality
right ovary	UBERON:0002118	44.20	gold quality
pancreas	UBERON:0001264	44.13	gold quality
upper leg skin	UBERON:0004262	44.11	silver quality
bone marrow	UBERON:0002371	43.65	gold quality
ventricular zone	UBERON:0003053	43.40	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
ovary	UBERON:0000992	42.97	gold quality
vermiform appendix	UBERON:0001154	42.12	gold quality
colonic epithelium	UBERON:0000397	41.73	gold quality
left ovary	UBERON:0002119	41.58	gold quality
caecum	UBERON:0001153	41.51	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6075	yes	5.64
E-ANND-3	yes	4.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting NLRP11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-573	99.55	67.44	955
HSA-MIR-5571-5P	99.49	66.99	1764
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-4795-5P	99.11	66.90	876
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-500A-5P	98.76	69.13	1241
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-4540	96.90	67.46	473
HSA-MIR-324-5P	95.68	65.20	560

Literature-anchored findings (GeneRIF, showing 4)

• Using MAVS as a platform, NLRP11 degrades TRAF6 to attenuate the production of type I IFNs as well as virus-induced apoptosis. Our findings reveal the regulatory role of NLRP11 in antiviral immunity by disrupting MAVS signalosome. (PMID:29097393)
• Data suggest that NLRP11 plays novel role in myeloid cells and B-lymphocytes (where NLRP11 expression is high); expression of NLRP11 in both tumor and non-tumor cell lines down-regulates NFkappaB and interferon type I signaling responses. (PMID:29301940)
• Adenosine-Induced NLRP11 in B Lymphoblasts Suppresses Human CD4(+) T Helper Cell Responses. (PMID:32832566)
• NLRP11 is a pattern recognition receptor for bacterial lipopolysaccharide in the cytosol of human macrophages. (PMID:37478192)

Cross-species orthologs

0 orthologs

Paralogs (20): NLRP2 (ENSG00000022556), NLRP1 (ENSG00000091592), NOD1 (ENSG00000106100), NLRC5 (ENSG00000140853), NLRP12 (ENSG00000142405), NLRP14 (ENSG00000158077), NLRP4 (ENSG00000160505), NLRX1 (ENSG00000160703), NLRP3 (ENSG00000162711), NOD2 (ENSG00000167207), NLRP7 (ENSG00000167634), NLRC3 (ENSG00000167984), NLRP5 (ENSG00000171487), NLRP13 (ENSG00000173572), NLRP6 (ENSG00000174885), CIITA (ENSG00000179583), NLRP8 (ENSG00000179709), NLRP10 (ENSG00000182261), NLRP9 (ENSG00000185792), PYDC2 (ENSG00000253548)

Protein

Protein identifiers

NACHT, LRR and PYD domains-containing protein 11 — P59045 (reviewed: P59045)

Alternative names: Nucleotide-binding oligomerization domain protein 17, PAAD-and NACHT domain-containing protein 10, PYRIN-containing APAF1-like protein 6

All UniProt accessions (4): P59045, K7EMN8, K7EQV0, K7ESF9

UniProt curated annotations — full annotation on UniProt →

Function. Involved in inflammation.

Similarity. Belongs to the NLRP family.

Isoforms (3)

UniProt ID	Names	Canonical?
P59045-1	1	yes
P59045-2	2
P59045-3	3

RefSeq proteins (5): NP_001284672, NP_001372380, NP_001372382, NP_001381823, NP_659444 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR004020	DAPIN	Domain
IPR007111	NACHT_NTPase	Domain
IPR011029	DEATH-like_dom_sf	Homologous_superfamily
IPR020611	Cu2_ascorb_mOase_CS-1	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR041075	NOD1/2_WH	Domain
IPR041267	NLRP_HD2	Domain
IPR050637	NLRP_innate_immun_reg	Family

Pfam: PF02758, PF05729, PF13516, PF17776, PF17779

UniProt features (16 total): repeat 6, sequence variant 3, domain 2, splice variant 2, chain 1, sequence conflict 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P59045-F1	85.34	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 153–160

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 32 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GOBP_INFLAMMATORY_RESPONSE, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, HATADA_METHYLATED_IN_LUNG_CANCER_DN, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_DEFENSE_RESPONSE, GARY_CD5_TARGETS_UP, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_MONOOXYGENASE_ACTIVITY, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN_REDUCED_ASCORBATE_AS_ONE_DONOR_AND_INCORPORATION_OF_ONE_ATOM_OF_OXYGEN, CIITA_TARGET_GENES, MAFG_TARGET_GENES

GO Biological Process (1): regulation of inflammatory response (GO:0050727)

GO Molecular Function (5): RNA binding (GO:0003723), ATP binding (GO:0005524), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced ascorbate as one donor, and incorporation of one atom of oxygen (GO:0016715), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
inflammatory response	1
regulation of defense response	1
regulation of response to external stimulus	1
nucleic acid binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
monooxygenase activity	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

664 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NLRP11	MEFV	O15553	815
NLRP11	RNF19A	Q9NV58	802
NLRP11	CASP1	P29466	562
NLRP11	PYCARD	Q9ULZ3	520
NLRP11	CLEC1A	Q8NC01	447
NLRP11	IFI16	Q16666	435
NLRP11	NAIP	Q13075	421
NLRP11	TMEM150B	A6NC51	399
NLRP11	CLEC4A	Q9UMR7	387
NLRP11	RNASEL	Q05823	375
NLRP11	NLRP6	P59044	372
NLRP11	NLRC4	Q9NPP4	371
NLRP11	PYDC1	Q8WXC3	368
NLRP11	OR9G4	Q8NGQ1	358
NLRP11	DTX4	Q9Y2E6	357

IntAct

3 interactions, top by confidence:

A	B	Type	Score
NLRP11	VIM	psi-mi:“MI:0915”(physical association)	0.400
CRY1	IGKV2D-30	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): NLRP11 (Proximity Label-MS), NLRP11 (Reconstituted Complex), NLRP11 (Cross-Linking-MS (XL-MS)), NLRP11 (Protein-RNA), SNRPD2 (Cross-Linking-MS (XL-MS)), NLRP11 (Cross-Linking-MS (XL-MS)), NLRP11 (Cross-Linking-MS (XL-MS)), NLRP11 (Cross-Linking-MS (XL-MS)), NLRP11 (Proximity Label-MS)

ESM2 similar proteins: A0A140LIF8, A0A2P1BRP3, A0A386CAB9, A0JN92, A1A4Y4, O14791, P27473, P59045, P86448, P86449, Q0GUM3, Q13075, Q3B7D9, Q3T9E4, Q3TL54, Q53G44, Q5NCI0, Q5RFJ8, Q60766, Q62293, Q66X01, Q66X03, Q66X05, Q66X22, Q6AYC2, Q6ZSC3, Q7Z745, Q84WJ0, Q86W28, Q8BV66, Q8BVM9, Q8C6J9, Q8CBA2, Q8CCN1, Q8TCB0, Q8TCY9, Q8TD90, Q90597, Q99388, Q99J64

Diamond homologs: A0A386CAB9, A1Z198, A6QLE5, B0FPE9, D4A523, D9I2F9, D9I2G1, D9I2G3, D9I2G4, D9I2H0, E9Q5R7, O15553, P10775, P13489, P29315, P59044, P59045, P59046, Q0GKD5, Q288C4, Q2LKU9, Q2LKV2, Q2LKV5, Q2LKW6, Q3TKR3, Q63035, Q647I9, Q66X01, Q66X03, Q66X19, Q6B966, Q7RTR0, Q86W24, Q86W25, Q86W26, Q86W28, Q8BU40, Q8C6J9, Q8CCN1, Q8HZP9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

185 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	140
Likely benign	15
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1898 predictions. Top by Δscore:

Variant	Effect	Δscore
19:55792299:A:AC	donor_gain	1.0000
19:55792300:C:CC	donor_gain	1.0000
19:55805175:C:CA	donor_gain	1.0000
19:55785868:AAGCC:A	acceptor_loss	0.9900
19:55785870:GC:G	acceptor_gain	0.9900
19:55785871:CC:C	acceptor_gain	0.9900
19:55785872:C:CA	acceptor_loss	0.9900
19:55785872:C:CC	acceptor_gain	0.9900
19:55785873:T:G	acceptor_loss	0.9900
19:55789265:C:CT	donor_gain	0.9900
19:55789396:CAGA:C	acceptor_gain	0.9900
19:55789400:C:CC	acceptor_gain	0.9900
19:55792294:GACTT:G	donor_loss	0.9900
19:55792295:ACTT:A	donor_loss	0.9900
19:55792296:CT:C	donor_loss	0.9900
19:55792297:TTACT:T	donor_loss	0.9900
19:55792298:TACTG:T	donor_loss	0.9900
19:55792299:ACTGA:A	donor_loss	0.9900
19:55792300:C:A	donor_loss	0.9900
19:55792303:AAGCT:A	donor_gain	0.9900
19:55792342:CG:C	donor_gain	0.9900
19:55792467:CTAAC:C	acceptor_gain	0.9900
19:55792468:TAAC:T	acceptor_gain	0.9900
19:55792469:AACCT:A	acceptor_loss	0.9900
19:55792470:ACCTG:A	acceptor_loss	0.9900
19:55792473:T:A	acceptor_loss	0.9900
19:55796079:CA:C	donor_gain	0.9900
19:55796079:CACCA:C	donor_gain	0.9900
19:55796118:A:AC	donor_gain	0.9900
19:55796251:C:CC	acceptor_gain	0.9900

AlphaMissense

6861 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:55789303:G:C	N870K	0.993
19:55789303:G:T	N870K	0.993
19:55792459:G:C	C785W	0.992
19:55792375:A:C	N813K	0.991
19:55792375:A:T	N813K	0.991
19:55788960:A:G	L901S	0.990
19:55789319:A:G	L865P	0.990
19:55789304:T:A	N870I	0.989
19:55809827:A:C	S261R	0.989
19:55809827:A:T	S261R	0.989
19:55809829:T:G	S261R	0.989
19:55788881:A:C	N927K	0.987
19:55788881:A:T	N927K	0.987
19:55788975:A:G	L896P	0.987
19:55807943:A:G	L638P	0.987
19:55789305:T:A	N870Y	0.986
19:55789387:A:C	C842W	0.986
19:55807992:A:G	W622R	0.986
19:55807992:A:T	W622R	0.986
19:55788965:G:C	C899W	0.985
19:55796170:A:G	L751P	0.985
19:55792376:T:A	N813I	0.984
19:55792461:A:G	C785R	0.984
19:55788897:A:G	L922P	0.983
19:55789262:A:G	L884S	0.983
19:55789389:A:G	C842R	0.983
19:55789397:A:G	L839P	0.983
19:55792304:A:G	L837P	0.983
19:55792460:C:T	C785Y	0.983
19:55809933:A:G	F226S	0.983

dbSNP variants (sampled 300 via entrez): RS1000011416 (19:55797689 A>T), RS1000035203 (19:55800098 C>G,T), RS1000077390 (19:55794078 G>A), RS1000128420 (19:55827641 T>A), RS1000167983 (19:55828036 A>G), RS1000240626 (19:55819180 C>G), RS1000241939 (19:55837339 G>A), RS1000270263 (19:55820995 T>C), RS1000294538 (19:55819406 C>T), RS1000363351 (19:55791410 A>G), RS1000413219 (19:55816177 C>T), RS1000415755 (19:55791680 C>G,T), RS1000495226 (19:55803883 A>G), RS1000561 (19:55797111 A>C,G,T), RS1000675174 (19:55808864 T>C)

Disease associations

OMIM: gene MIM:609664 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000266_2	Multiple sclerosis (severity)	4.000000e-06
GCST001381_7	Menopause (age at onset)	9.000000e-10
GCST001850_49	Major depressive disorder	6.000000e-06
GCST005312_14	Menopause (age at onset)	6.000000e-85
GCST005312_15	Menopause (age at onset)	3.000000e-13
GCST005312_16	Menopause (age at onset)	8.000000e-16
GCST008363_9	Offspring birth weight	5.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004704	age at menopause
EFO:0004344	birth weight
EFO:0005939	parental genotype effect measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — NOD-like receptor family

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	2
butyraldehyde	increases expression	1
nickel sulfate	increases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
N-Nitrosopyrrolidine	increases expression	1
Ozone	increases expression	1
Aflatoxin B1	increases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome